Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurological disorders
Biotech
Vigil's rare brain disease drug flunks phase 2 study
The trial missed its biomarker and efficacy endpoints, prompting the Sanofi-bound biotech to stop a long-term extension trial of the TREM2 agonist.
Nick Paul Taylor
Jun 4, 2025 9:45am
Oligomerix small molecule tamps down tau tangles in mice
Mar 14, 2025 12:30pm
Irish biotech's inhaled drug reduces depression in phase 2 trial
Feb 3, 2025 8:15am
Astellas pays Sangamo $20M to boost neurological gene therapies
Dec 19, 2024 7:13am
Acadia inks $582M biobucks pact for Danish biotech's neuro asset
Nov 26, 2024 5:00pm
Kronos shelves sole clinical drug over neurological side effects
Nov 14, 2024 5:14am
